Co-Authors
This is a "connection" page, showing publications co-authored by GREGORY N FULLER and SHIAO-PEI WEATHERS.
Connection Strength
0.472
-
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
Score: 0.186
-
Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032.
Score: 0.057
-
A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022 06 01; 11(2):CNS87.
Score: 0.054
-
Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab079.
Score: 0.050
-
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
Score: 0.046
-
Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther. 2019 05; 18(5):991-1000.
Score: 0.043
-
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66.
Score: 0.036